Marshall Wace
VIRX

Marshall Wace’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Marshall Wace’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-29,001
Closed -$106K – 4159
2021
Q4 		$106K Buy
+29,001
New +$155K ﹤0.01% 3363
2015
Q3 		– Sell
-155
Closed -$98K – 1085
2015
Q2 		$98K Buy
+155
New +$82.4K ﹤0.01% 858

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's VIRX Position: Q1 2022 in Review

Marshall Wace sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022, closing a stake of 29,001 shares — an estimated $106K sold.

Marshall Wace first reported a position in VIRX in Q2 2015 and held it in 2 quarters. The position peaked at $106K in Q4 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

  • Marshall Wace reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 29,001 Viracta Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $106K.
  • Marshall Wace first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Marshall Wace's Viracta Therapeutics, Inc. Common Stock position peaked at $106K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.